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Abstract
Introduction: An unidentified population of peripheral blood mononuclear cells (PBMCs) express Ras guanine
nucleotide releasing protein 4 (RasGRP4). The aim of our study was to identify the cells in human blood that
express hRasGRP4, and then to determine if hRasGRP4 was altered in any patient with rheumatoid arthritis (RA).
Methods: Monocytes and T cells were purified from PBMCs of normal individuals, and were evaluated for their
expression of RasGRP4 mRNA/protein. The levels of RasGRP4 transcripts were evaluated in the PBMCs from healthy
volunteers and RA patients by real-time quantitative PCR. The nucleotide sequences of RasGRP4 cDNAs were also
determined. RasGRP4 protein expression in PBMCs/monocytes was evaluated. Recombinant hRasGRP4 was
expressed in mammalian cells.
Results: Circulating CD14
+ cells in normal individuals were found to express hRasGRP4. The levels of the hRasGRP4
transcript were significantly higher in the PBMCs of our RA patients relative to healthy individuals. Sequence
analysis of hRasGRP4 cDNAs from these PBMCs revealed 10 novel splice variants. Aberrantly spliced hRasGRP4
transcripts were more frequent in the RA patients than in normal individuals. The presence of one of these
abnormal splice variants was linked to RA. The levels of hRasGRP4 protein in PBMCs tended to be lower. As
expected, the defective transcripts led to altered and/or nonfunctional protein in terms of P44/42 mitogen-
activated protein (MAP) kinase activation.
Conclusions: The identification of defective isoforms of hRasGRP4 transcripts in the PBMCs of RA patients raises
the possibility that dysregulated expression of hRasGRP4 in developing monocytes plays a pathogenic role in a
subset of RA patients.
Introduction
Ras guanine nucleotide releasing protein (RasGRP) 4 is a
calcium-regulated guanine nucleotide exchange factor
(GEF) and diacylglycerol (DAG)/phorbol ester receptor.
The mouse, rat and human cDNAs and genes that
encode this signaling protein were initially cloned during
a search for novel transcripts selectively expressed in
mast cells (MCs) by Yang and coworkers [1-3]. Others
isolated a hRasGRP4 cDNA while searching for
transcripts that encode oncogenic proteins in a patient
with acute myeloid leukemia [4]. Mouse and human
RasGRP4 mRNAs are abundant in an undefined popula-
tion of peripheral blood mononuclear cells (PBMCs)
[1,3]. Although all examined mature MCs in the tissues
of normal humans and mice express RasGRP4 [1-3], it
remains to be determined whether this signaling protein
is expressed in another cell type.
Different isoforms of mouse, rat and human RasGRP4
[1,2,5] and its family member RasGRP1 have been iden-
tified which in each instance are caused by variable spli-
cing of their precursor transcripts. For example, the lag
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resembles systemic lupus erythematosus (SLE) due to a
failure to properly process the precursor mRasGRP1
transcript [6]. In support of these mouse data, we identi-
fied a subset of SLE patients that lacks the normal iso-
form of hRasGRP1 in their circulating T cells and
PBMCs [7]. Splice variants of the hRasGRP4 transcript
have been detected in the PBMCs of a limited number
of patients with mastocytosis and asthma, as well as the
HMC-1 cell line established from a patient with MC
leukemia [1]. These data raised the possibility of altered
expression of hRasGRP4 in some disease states.
RasGRP4 regulates the expression of many genes in
the HMC-1 line, including the transcripts that encode
prostaglandin D2 synthase, the transcription factor
GATA-1, and the interleukin (IL)-13 inhibitory receptor
IL13Ra2 [5,8]. In support of these in vitro data, the
mature RasGRP4
+ MCs that reside in the peritoneal cav-
ity of mice and rats preferentially metabolize arachido-
nic acid to prostaglandin D2 [9] due to their high levels
prostaglandin D2 synthase [10].
Rheumatoid arthritis (RA) is a chronic inflammatory
disease characterized by a distinctive synovitis resulting
in progressive joint destruction. Although several genetic
predispositions and environmental factors are known to
increase the risk of developing RA, its pathogenesis is
not completely understood [11,12]. MCs have been
implicated in RA and experimental models of this auto-
immune disorder. Tissue specimens isolated from the
joints of RA patients contain increased numbers of
hTryptase-b
+ MCs, and these effecter cells tend to loca-
lize at the junction of the pannus and cartilage, as well
a si na r e a sw h e r et h ep a n n u si si n v a d i n gc o r t i c a lb o n e
[13-15]. MC-deficient WBB6F1-Kit
W/Kit
W-v and
WCB6F1-Kitl
Sl/Kitl
Sl-d mice are resistant to arthritis
induced by autoantibodies against collagen, glucose-6-
phosphate isomerase, or methylated bovine serum albu-
min (BSA) [16-19]. Activated MCs produce a diverse
array of proinflammatory factors, including varied gran-
ule serine proteases. In the K/BxN mouse serum-trans-
f e r[ 2 0 ]a n dm e t h y l a t e dB S A / I L-1 [19] arthritis models,
MC-restricted tryptase￿heparin complexes regulate the
accumulation of neutrophils and the loss of aggrecan
proteoglycans in the cartilage.
MCs, monocytes, and macrophages originate from a
common progenitor in humans [21], and hTryptase-b
+
MCs can be generated from human cord blood and
PBMCs [22]. Circulating myeloid cells also differentiate
into tissue-resident macrophage and dendritic cells.
Macrophages are abundant in the RA synovium. Upon
activation, these immune cells release substantial
amounts of inflammatory cytokines and growth factors
(for example, IL-1b, IL-6, tumor necrosis factor-a
(TNF-a) and transforming growth factor-b)t h a t
participate in synovial inflammation and hyperplasia
[23-25]. Thus, MCs and myeloid cells play pivotal roles
in the pathophysiology of RA.
In the present study, we discovered that the CD14
+
myeloid cells in human PBMCs express hRasGRP4. As
dysregulation of hRasGRP1 occurs in a subset of
patients with SLE [7], we hypothesized that hRasGRP4
might be abnormally expressed in the PBMCs that give
rise to MCs, macrophages, and possibly other cell types
in some patients with RA. We now report that abnormal
splicing of the hRasGRP4 transcript is frequent in the
PBMCs of RA patients. The accumulated data raise the
possibility that altered expression of hRasGRP4 occurs
in a subset of RA patients.
Materials and methods
Healthy individuals and patients with RA and other
autoimmune disorders
Forty-two apparently healthy Japanese individuals (6
males and 36 females, 49.8 ± 6.7 years old, mean ± SD)
and 57 Japanese patients with RA (16 males and 41
females, 61.1 ± 13.5 years old, mean ± SD) were studied.
All patients in the latter cohort were diagnosed as hav-
ing RA by rheumatologists based on the American Col-
lege of Rheumatology 1987 revised criteria for the
classification of this autoimmune disease [26]. The
mean disease duration of our RA patients was 126
months (range = 0 to 504 months). The Disease Activity
Score in 28 joints (DAS28ESR4) [27] at the time of ana-
lysis was 3.3 ± 1.3 (range = 1.3 to 6.8). Fifty-one (89%)
of these patients were receiving anti-rheumatic drugs.
Thirty-seven (65%), 13 (27%), 7 (12%), and 39 (68%) of
these patients were on methotrexate, sulphasalazine,
bucillamine and prednisolone, respectively. Three
patients were on biological agents. Thirty-six patients
with other autoimmune diseases served as autoimmune
controls. The patients in this control group had SLE (n
= 10), polymyositis/dermatomyositis (n = 8), systemic
sclerosis (n = 8), or the Sjögren’ss y n d r o m e( n = 10).
Our study was approved by the Human Ethics Commit-
tee of Hokkaido University Graduate School of Medi-
cine, and informed consent was obtained from each
subject.
Cell separation
PBMCs were collected from approximately 10 ml of the
peripheral blood drawn from healthy individuals or
patients using Ficoll paque PLUS (Amersham Bios-
ciences, Uppsala, Sweden). CD14
+ cells were purified
from the resulting PBMCs using micro beads and a
magnetic cell sorting separation unit (Miltenyi Biotec,
Bergisch Gladbach, Germany). CD14, CD3, and CD19
micro beads were used to enrich non-monocyte, non-T
cell, and non-B cells in the PBMCs by negative
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entiated cells including mast cell progenitors [28]. T
cells were also purified from the PBMCs using the
RosetteSep human T -cell enrichment cocktail (StemCell
Technology, Vancouver, BC, Canada). The purities of
the obtained cells were routinely > 85% for CD14
+ mye-
loid cells and > 95% for CD3
+ T cells, as assessed on a
FACS Calibur flow cytometer (BD Biosciences, San Jose,
CA, USA) using phycoerythrin-labeled anti-CD14 and
anti-CD3 antibody (BD Biosciences), respectively.
Evaluation of hRasGRP4 transcript levels, and isolation of
novel hRasGRP4 transcripts in RA patients
Total RNA was collected from whole PBMCs and sepa-
rated cells using RNeasy Mini kits (Qiagen, Valencia,
CA, USA). The obtained transcripts were converted into
cDNAs employing QuantiTect Reverse Transcription
kits (Qiagen). The coding regions of the hRasGRP4
cDNAs were then amplified by a PCR method using the
forward 5’-AGCATGAACAGAAAAGACAGTAAG-3’
and the reverse 5’-TGTCTAGGAATCCGGCTTGGA-3’
primers which correspond to nucleotide sequences
residing at the translation-initiation and -termination
sites in the normal hRasGRP4 transcript noted at Gen-
Bank accession number [NM:170604], respectively. After
a heat-denaturation step, each of the 25 cycles of the
subsequent PCR steps consisted of a 15-s denaturing
step at 94°C, a 30-s annealing step at 59°C, and a 1.5-
minute extension step at 72°C. The transcript that
encodes the housekeeping protein human glyceralde-
hyde-3-phosphate dehydrogenase (hGAPDH) served as a
control in these transcript analyses.
A real-time quantitative PCR (qPCR) approach was
used to monitor the overall levels of the hRasGRP4
transcripts in fractionated cell lineages and in PBMCs
from 38 healthy individuals, 41 patients with RA, and 36
patients with other rheumatic diseases. In these experi-
ments, the level of the hRasGRP4 transcript was nor-
malized to that of the hGAPDH transcript using an ABI
Prism 7000 Sequence Detection System (Applied Biosys-
tems, Foster City, CA, USA) and TaqMan MGB probes
specific for hRasGRP4 (Hs00364781m1) and hGAPDH
(Hs00266705m1) (Applied Biosystems). We chose a
hRasGRP4-specific primer set in these qPCRs that
recognizes the junction nucleotide sequence located
between exons 7 and 8. Relative quantification was per-
formed using the comparable cycle threshold (CT)
method in which ΔCT i st h el e v e lo ft h eh R a s G R P 4
transcript in the RNA sample relative to that of the
hGAPDH transcript. The difference in the expression of
the hRasGRP4 transcripts among each sample was
defined as fold changes in mRNA levels by 2
-ΔΔCT.
T h en u c l e o t i d es e q u e n c e so f2 9 5h R a s G R P 4t r a n -
scripts were also determined using RNA isolated from
16 healthy individuals, 23 patients with RA (18 under
treatment and 5 untreated), and 20 patients with other
autoimmune diseases (5 with SLE, 5 with Sjögren’s syn-
drome, 5 with inflammatory myositis and 5 with sys-
temic sclerosis. In each instance, the generated
hRasGRP4 cDNAs were subcloned into pcDNA3.1 V5-
His-TOPO (Invitrogen, Carlsbad, CA, USA), and five
arbitrarily selected cDNAs from each individual were
sequenced using an ABI Prism 3130 Genetic Analyzer
(Applied Biosystems).
Evaluation of hRasGRP4 transcript levels in macrophages
and osteoclasts
Macrophages were differentiated from peripheral blood
CD14
+ cells in the presence of several cytokines using
previously reported technology [29]. Briefly, macro-
phages were obtained by culturing CD14
+ cells in the
presence of M-CSF (50 ng/ml). After seven days incuba-
tion at 37°C in a humid chamber, differentiated cells
were collected. Osteoclasts were differentiated in the
presence of M-CSF (33 ng/ml) and RANK-ligand (66
ng/ml) (Lonza Walkersville, Inc., Walkersville, MD,
USA). After 14 days, cells were collected. RNA was col-
lected from each cell lineage and hRasGRP4 expression
was examined for both cell lineages using TaqMan
MGB probes specific for hRasGRP4 and hGAPDH.
Expression of cathepsin-K, one of the specific markers
for differentiated osteoclasts, was evaluated for osteo-
clasts to confirm their differentiation (Probe ID:
Hs00166156m1) (Applied Biosystems)[30]. RasGRP1
expression was also examined in the PBMC and in
osteoclasts (Probe ID: Hs00996734m1) (Applied
Biosystems).
Use of an anti-peptide approach to obtain antibodies that
recognize the N terminus of hRasGRP4
Rabbit anti-hRasGRP4 antibodies were generated against
the novel 14-mer synthetic peptide
MNRKDSKRKSHQEC that corresponds to the N termi-
nus of the normal isoform of hRasGRP4. A Basic Local
Alignment Search Tool (BLAST) protein search revealed
no similar sequence in any other known human protein.
Using this synthetic peptide, rabbit polyclonal anti-
hRasGRP4 antibodies were generated and purified, as
previously described for the generation of rabbit anti-
hRasGRP1 antibodies [7]. The specificity of the gener-
ated anti-hRasGRP4 antibodies was confirmed by
absorption assay using the same peptide as used for
immunization both in immunoblot and in immunohisto-
chemistry using lysates of epithelial cell line HEK-293
(line CRL-1573; American Type Culture Collection)
transfected with expression constructs encoding
hRasGRP4 with the C-terminal V5 epitope tag (data not
shown).
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mammalian cell line and cell-free transcription-translation
assay
Expression constructs encoding hRasGRP4 and its splice
variants (variant 5 and 6) were transfected into the
epithelial cell line HEK-293 that normally lacks
hRasGRP4. The cDNAs that encode normal RasGRP4
and its splice variants were subcloned into pcDNA3.1
V5-His-TOPO (Invitrogen). We made hRasGRP4 con-
structs with or without C-terminal V5 tag. Transfections
were performed using Lipofectamine 2000 Reagent
(Invitrogen). The presence of the RasGRP4 at the pro-
tein level was evaluated by a SDS-PAGE immunoblot
and by immunohistochemistry. A cell-free transcription:
translation assay was performed using the PROTEIN-
script II T7 kit (Ambion, Austen, TX, USA) according
to the manufacturer’s instruction. Constructs encoding
full-length normal RasGRP4, splice variant 5 and splice
variant 6 were subjected to the system and evaluated by
immunoblotting.
Immunohistochemistry
Immunohistochemistry was carried out on PBMC-
derived CD14
+ myeloid cells and T cells, and
hRasGRP4-expressing HEK293 cells. Non-transfected
HEK293 cells were used as negative control. A total of
500,000 cells in each instance were placed on a glass
slide using a Shandon Cytospin 4 Cytocentrifuge
(Thermo Fisher Scientific Inc., Waltham, MA, USA).
hRasGRP4
+ HEK293 cells were cultured on a Lab-Tek II
Chamber Slide System (Nalge Nunc International,
Rochester, NY, USA). The prepared slides were fixed
and permeabilized with 4% paraformaldehyde and 0.2%
saponin (eBioscience, San Diego, CA, USA). Endogenous
peroxide was quenched using a 3% solution of hydrogen
peroxide in absolute methanol; blocking was done with
a 3% solution of BSA in phosphate-buffered saline.
Immunohistochemistry was performed using our rabbit
anti-hRasGRP4 antibodies (1 μg/ml) or rabbit anti-b-
actin antiserum (Sigma-Aldrich, St. Louis, MO, USA)
diluted 1:80, followed by the relevant biotinylated anti-
bodies and peroxidase-conjugated streptavidin (Nichirei
Biosciences, Tokyo, Japan). Irrelevant rabbit IgG served
as another negative control for our anti-hRasGRP4 anti-
bodies. An absorption staining procedure was performed
using a cocktail mixture of our anti-hRasGRP4 antibo-
dies (1 μg/ml) and synthetic hRasGRP4-derived peptide
(100 ng/ml). The immunoreaction was visualized using
a 0.6% hydrogen peroxide (Nichirei Biosciences) solution
containing 3,3’-diaminobenzidine tetrahydrochloride
(DAB). Nuclear staining was done with hematoxylin,
and the resulting stained cells were examined by light
microscopy.
Immunoblotting
After conjugation of our anti-hRasGRP4 antibodies with
horse-radish peroxidase using Lightning-link HRP con-
jugation kit (Innova Biosciences, Cambridge, UK), the
levels of hRasGRP4 protein in CD14
+ peripheral blood
cells were evaluated using an immunoblot approach, as
previously described [7]. Densities of immune-reactive
bands were measured using ImageJ software supported
by NIH [31]. Anti-phospho-P44/42 mitogen-activated
protein kinase (MAPK) (Erk1/2) antibodies and anti-
pan-P44/42 MAPK antibodies were purchased from Cell
Signaling Technologies (Beverly, MA, USA).
Statistical analysis
T h ec h i - s q u a r et e s to rF i s h e r ’se x a c tt e s tw a su s e dt o
compare the frequencies of the identified hRasGRP4 var-
iants in our patient’s PBMCs. To evaluate the expression
of a specific hRasGRP4 isoform, we first defined the nor-
mal range of ΔΔ-CT value as the mean ± 2 SD of the
healthy volunteers. The levels of the hRasGRP4 transcript
in the RA patients were then quantitated. The expression
of hRasGRP4 transcripts in control individuals and
patients were compared using Fisher’s exact test. The
incidence of splice variants and expression levels of this
gene were compared by using Mann-Whitney’s U-test. In
all of the statistical analyses, JMP version 9.0 software
(SAS Institute Inc., Cary, NC, USA) was utilized.
Results
Identification of hRasGRP4 mRNA and protein isoforms in
CD14
+ myeloid cells
Circulating in vivo-differentiated, unfractionated human
PBMCs and PBMC-derived CD3
+ T cells, CD14
+ mye-
loid cells, and CD14
-/CD3
-/CD19
- cells were initially
evaluated for the presence of hRasGRP4 mRNA using a
semi-quantitative reverse transcriptase-PCR approach.
Employing primers that correspond to the start and end
of the protein’s coding domain, the approximately 1.5-
kb cDNA that encodes the normal isoform of hRasGRP4
was found to be abundant in the circulating CD14
+ cells
present in the PBMCs of normal individuals (Figure
1A), as previously found [1]. The presence of large
amounts of hRasGRP4 mRNA in these cells was con-
firmed by a real-time qPCR approach using different
primers (Figure 1B). The non-T, non-B, non-monocyte
population of CD14
-/CD3
-/CD19
- cells in these PBMCs
contained relatively lower amounts of hRasGRP4
mRNA, and the level of the hRasGRP4 transcript was
below detection in enriched peripheral blood T cells. In
agreement with these transcript data, the CD14
+ cells
purified from in vivo-differentiated human PBMCs con-
tained hRasGRP4 protein as assessed immunohisto-
chemically (Figure 1C). As expected, immunoreactive
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Page 4 of 13Figure 1 Evaluation of hRasGRP4 expression in peripheral blood. A, Evaluation of hRasGRP4 mRNA levels in unfractionated peripheral blood
mononuclear cells (PBMCs), PBMC-derived CD14
+ cells, CD14
-/CD3
-/CD19
- cells and T cells isolated from healthy individuals. A RT-PCR/gel
separation approach using an exon 1/exon 17 primer set in the hRasGRP4 gene was carried out to evaluate transcript expression in each cell
type. Human glyceraldehyde-3-phosphate dehydrogenase (hGAPDH)-specific primers were used in the lower panels as positive controls.
Representative results from three independent experiments are shown. B, A qPCR approach using a primer set that recognizes the junctional
part of exon 7 and exon 8. Delta-CT of hRasGRP4 transcript level relative to the hGAPDH transcript in CD14
+ cells was defined as 1. qPCR assay
was done in a triplicate manner for three times and the error bars indicate standard errors. C, Immunohistochemistry; PBMC-derived CD14
+
myeloid cells and T cells were stained with anti-hRasGRP4 antibody (top panels). For negative and positive controls, HEK293 cells that differed in
their levels of hRasGRP4 protein also were stained with the anti-hRasGRP4 antibodies. For additional controls, replicate cells were stained with
anti-b-actin antibodies (middle panels) or irrelevant rabbit IgG (bottom panels). Representative results from three to four procedures are shown.
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Page 5 of 13hRasGRP4 protein was not detected in T cells. Trans-
fected HEK293 cells that differed in their levels of
hRasGRP4 served as positive and negative controls.
hRasGRP4 transcript levels during CD14
+ cell
development into macrophages and osteoclasts
hRasGRP4 transcript levels decreased while CD14
+ per-
ipheral blood cells differentiated into macrophages
(Additional file 1/Figure s1A). RasGRP4 expression was
diminished in osteoclasts (Additional file 1/Figure s1B,
left panel), which was no tc o u n t e r e da tl e a s tb y
RasGRP1 (data not shown). Development of multi-
nucleated osteoclasts was confirmed by light micro-
scope. Elevated Cathepsin K expression was confirmed
in these cells (Additional file 1/Figure s1B, right panel).
Quantitative evaluation of hRasGRP4 transcripts in
patients with RA and other autoimmune diseases
We designated normal levels of hRasGRP4 transcripts in
PBMCs as the mean ± 2 SD of that in the PBMCs of
healthy individuals. The levels of the hRasGRP4 tran-
scripts were higher than the normal levels in 41% of our
RA patients (P < 0.0001) (Figure 2). The levels of the
hRasGRP4 transcript also were higher in the PBMCs of
patients that had other autoimmune diseases: SLE (P =
0.0009), polymyositis/dermatomyositis (P = 0.02), sys-
temic sclerosis (P = 0.006), and Sjögren’s syndrome (P =
0.0004). Thus, the presence of increased amounts of
hRasGRP4 mRNA in PBMCs appears to be a useful
marker for the identification of patients with autoim-
mune disorders. Despite these data, the levels of the
hRasGRP4 transcript in the PBMCs of our RA patients
was not correlated with the examined clinical features
(for example, age, disease duration, DAS28, erythrocyte
sedimentation rate (ESR), or serum matrix metallopro-
teinase 3 (MMP3)) (data not shown). Also in healthy
individuals, RasGRP4 expression levels were not affected
by age (data not shown). In addition, the levels of
hRasGRP4 transcript were not affected by the ratios of
monocytes in the PBMCs (represented by the sum
Figure 2 Evaluation of hRasGRP4 mRNA levels in PBMCs. A qPCR approach was used to quantify the overall levels of hRasGRP4 transcripts in
the peripheral blood mononuclear cells (PBMCs) from healthy individuals and patients with rheumatoid arthritis (RA) and other rheumatic
diseases such as SLE, Sjögren’s syndrome (SS), systemic sclerosis (SSc), and polymyositis/dermatomyositis (PM/DM). Shown are the relative
quantities (RQ) of human glyceraldehyde-3-phosphate dehydrogenase (hGAPDH)-corrected levels of the hRasGRP4 transcript in each sample.
One of the healthy individuals was assigned to determine the value of 1. In all of the healthy individuals and patients, assays were done in a
triplicate manner and mean values are plotted in the figure. Normal upper limit of the transcript level was defined as mean transcript level +
2SD of the healthy controls. Numbers of the patients whose hRasGRP4 transcript levels are above the normal upper limit were evaluated using
Fisher’s exact test.
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patients (Additional file 2/Figure s2). Therefore, it
would be acceptable for a screening to evaluate
hRasGRP4 transcript levels using PBMC instead of
using purified monocytes.
Identification of 10 novel hRasGRP4 transcripts that have
undergone defective splicing of the precursor transcript
Sequence analysis of the hRasGRP4 cDNAs from 16
healthy individuals and 23 RA patients (including 5
patients on no therapy) revealed 12 isoforms of hRasGRP4
caused by alternative splicing of its precursor transcript
(Figure 3). Four previously identified isoforms of
hRasGRP4 have been designated as splice variants 1 to 4
[1]. Two of the alternative splicing isoforms identified in
our RA patients correspond to variants 1 and 2. However,
the other 10 isoforms (designated as variants 5 to14) have
not been previously described. These novel splice variants
that lack the entire exon 9 (splice variant 5, GenBank
accession number: (FJ768677)); the first 207 nucleotides of
exon 9 (splice variant 6, GenBank accession number:
(FJ768678)); exon 7 (splice variant 7, GenBank accession
number: (FJ768679)); exons 7, 8, and 9 (splice variant 8,
GenBank accession number: (FJ768680]); exons 7 and 8
(splice variant 10, GenBank accession number:
(FJ768682)); exon 6 (splice variant 11); and 12 nucleic
acids at the 5’ end of exon 12 (splice variant 13). Intron 14
had not been removed in splice variant 9 (GenBank acces-
sion number: (FJ768681)); 143 nucleotides from intron 11
had not been removed in splice variant 12; and 143
nucleotides from intron 11 and 95 nucleotides from intron
14 had not been removed from splice variant 14.
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Figure 3 Novel transcripts that encode abnormal hRasGRP4 isoforms in the PBMCs. The top panel shows the exon structure and
corresponding functional motifs of hRasGRP4, which include the Ras exchange motif (REM), CDC25-like GEF domain (CDC25 box), calcium-
binding EF hands, and diacylglycerol -binding C1 domain. Splice variants 5 to 14 in the lower panel correspond to the 10 new hRasGRP4
transcripts identified in our RA patients. If translated, the number of amino acids (AA) in each expressed isoform is indicated. Eighty hRasGRP4-
specific cDNAs were isolated and sequenced from 16 healthy individuals. Two, 13, 1, 1 and 1 of these cDNAs corresponded to splice variants 1,
5, 6, 7, and 8 respectively. The remaining 62 sequenced cDNAs in this control group corresponded to the normal, full-length hRasGRP4 isoform.
Ninety and 25 hRasGRP4-specific cDNAs were isolated and sequenced from 18 RA patients undergoing treatment and from five untreated RA
patients, respectively. The type and number of the identified defective transcripts in these patients are shown. One hundred hRasGRP4 cDNAs
from 20 patients with other autoimmune diseases were sequenced, resulting in 36 defective and 64 normal hRasGRP4 transcripts as shown.
Variants 1, 9, 12, and 14 possess a premature translation-termination codon (*). Intron 1 is 3.9 kb and many of the other introns in this
approximately 17.2 kb human gene are > 1 kb. Because the PCR approach used to identify and quantitate the new isoforms would miss an
isoform that contains intron 1, it is likely that additional splice variants exist in PBMCs that contain one or more large introns.
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Page 7 of 13The most frequently found abnormal hRasGRP4 tran-
script identified in our group of RA patients was splice
variant 5, which lacks the entire exon 9. Loss of this
exon does not cause a frame-shift abnormality or a pre-
mature translation-termination codon in the processed
transcript but does results in the loss of 92 amino acids
which correspond to the C-terminal half of the CDC25-
like catalytic domain in the signaling protein [1]. The
second most frequent isoform was variant 6 which
results in the loss of 69 of these same amino acids.
Splice variants 9, 12, and 14 are more severely altered
isoforms because they create in each instance a prema-
ture translation-termination codon. The hRasGRP4
splice variants as well as splice variant 6 were more fre-
quent in clone number in the PBMCs of our RA
patients (Table 1). Twenty clones corresponding to
splice variant 6 from our RA patients were not from a
few patients that express multiple clones of this variant.
The distribution of splice variant 6 was one clone from
eight RA patients and two clones from six RA patients.
None of our RA patients had more than half of splice
variant 6 from the sequenced clones. Except for splice
variant 6, the frequencies of these splice variants were
not significantly different in the PBMCs of patients with
other autoimmune diseases relative to that of healthy
subjects. Splice variant 6 was scarcely detected in the
PBMCs of normal individuals. In healthy subjects, fre-
quency of RasGRP4 splice variants was not related to
their age (data not shown). In RA patients, the presence
of splice variant 6 was not related to any evaluated clini-
cal features (that is, age, disease activity, serum MMP3
levels, disease duration, or therapy treatment) (Table 2).
However, this specific variant was more frequent in our
male RA patients. The levels of hRasGRP4 transcripts
evaluated by real-time qPCR were significantly high in
individuals who possess splice variant 6 (P = 0.02, calcu-
lated using Mann-Whitney’s U-test). Because abnormal
splicing of RasGRP4 was most evident in patients with
RA, we focused on RasGRP4 expression in RA patients
in the following study.
hRasGRP4 protein levels in the PBMCs and CD14
+
peripheral blood cells isolated from healthy individuals
and RA patients
The levels of hRasGRP4 protein were lower in the
PBMCs from many of our RA patients relative to that of
healthy control individuals (Figure 4A). Abnormal-sized
bands corresponding to splice variant 5 or 6 were scar-
cely detected by our immunoblot analysis, except that
patients 1 and 2 had detectable smaller-sized bands.
Although there remains a possibility that our antibodies
do not recognize alternatively-spliced isoforms, recombi-
nant hRasGRP4 splice variant 6 with C-terminal V5 tag
was recognized clearly by our anti-hRasGRP4 antibodies
and by anti-V5 antibody (data not shown). Most of our
RA patients express abnormal isoforms of the
hRasGRP4 transcript from simultaneously obtained sam-
ples (Table 3). The levels of hRasGRP4 protein in CD14
+ peripheral blood cells were also lower in RA patients
compared to those in healthy individuals (Figure 4B).
Recombinant hRasGRP4 protein using cell-free
transcription-translation assay and mammalian cell line
Full-length hRasGRP4, splice variant 5 and splice variant
6 were expressed at protein levels at expected sizes in a
cell-free transcription-translation assay (Figure 5A).
Similar protein expression was observed in mammalian
Table 1 Statistical analysis of hRasGRP4 isoforms in
healthy subjects and patients with RA and autoimmune
controls
normal variant
(%)
OR 95% CI P-value
Any variant
Healthy subjects 62 18 (22.5)
RA patients (total) 47 74 (67.3) 5.42 2.86 to
10.3
0.00000016
RA patients
(untreated)
9 16 (64.0) 6.12 2.32 to
16.2
0.00029
Autoimmune
controls
69 31 (31.0) 1.55 0.79 to
3.04
0.27
non-
variant 6
variant
6
OR 95% C.I. P-value
Variant 6
Healthy subjects 79 1 (1.3)
RA patients 95 20 (18.0) 16.6 2.18 to
126
0.00035
Autoimmune
controls
92 8 (8.0) 6.87 0.84 to
56.1
0.038
CI, confidential interval and P-values were calculated by Chi-square test to
evaluate the incidence of alternative splicing with healthy subjects and
patients groups. The frequency of variant 6 in each group was evaluated by
Fisher’s exact probability test. The percentage (%) of sequenced clones that
contained an aberrant hRasGRP4 transcript is also indicated. OR, odds ratio;
RA, rheumatoid arthritis
Table 2 Comparison of the clinical features between RA
patients with hRasGRP4 variant 6 and those without
variant 6 (-) variant 6 (+) P-value
Age (years) 62.6 ± 6.2 61.4 ± 11.2 0.96*
Male/female 0/10 6/7 0.012
†
DAS28(ESR4) 3.8 ± 1.2 3.4 ± 1.85 0.31*
MMP-3 307 ± 127 148 ± 109 0.057
Disease duration (months)
{mean (range)}
100 (0 to 492) 143 (0 to 504) 0.58*
Patients on therapy 4 8
Patients on no therapy 2 3 0.77
†
The P-values in the first four rows (*) were calculated using Mann-Whitney’s
U-test; the P-values (
†) were calculated by chi-square test with Yates’
correction. DAS28, The Disease Activity Score in 28 joints; MMP, matrix
metalloproteinase; RA, rheumatoid arthritis
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transfection with full-length RasGRP4 into HEK293
cells, P44/42 MAP kinase activation naturally occurred,
when compared to non-transfected cells (Figure 5B,
right panel). Whereas, transfection with splice variant 6
barely activated P44/42 M A P K .T h u s ,a se x p e c t e d ,
hRasGRP4 splice variant 6 was functionally defective for
the activation of Ras-Erk pathway.
Figure 4 Protein expression of hRasGRP4 in the peripheral blood evaluated by immunoblotting. A. Immunoblotting of peripheral blood
mononuclear cells from patients with RA and healthy controls. Lysates were prepared from peripheral blood mononuclear cells from patients
with rheumatoid arthritis (RA) and healthy controls. Approximately 3 μg of protein from each lysate was subjected to SDS-PAGE. Immunoblotting
was performed using peroxidase-conjugated anti-hRasGRP4 antibodies and anti-b-actin antibodies. PBMCs from four healthy individuals and six
RA patients were evaluated in panels A. B. Immunoblotting of circulating CD14
+ cells isolated from five healthy controls and six RA patients.
Table 3 Clinical profiles and sequenced hRasGRP4 cDNAs of the patients and healthy controls whose peripheral blood
samples were obtained simultaneously as those in Figure 4A
Age Sex DAS28 Treatment Clone 1 Clone 2 Clone 3 Clone 4 Clone 5
Healthy 1 32 F 0 none FL FL Variant 5 FL FL
Healthy 2 31 F 0 none FL FL Variant 5 Variant 6 FL
Healthy 3 38 F 0 none FL FL Variant 7 FL FL
Healthy 4 38 F 0 none FL FL FL FL
RA 1 70 M 3.22 MTX 8 mg/week
+ IFX
FL FL FL Variant 6 FL
RA 2 66 F 3.82 MTX 6 mg/week FL FL FL Variant 6 Variant 2
RA 3 61 F 2.17 MTX 10.5 mg/week
+ TAC 3 mg/day
Variant 5 Variant 5 Variant 5 Variant 5 Variant 5
RA 4 33 F 4.87 MTX 8 mg/week
+ PSL 5 mg/day
Variant 5 FL Variant 5 FL Variant 5
RA 5 78 M 2.65 MTX 6 mg/week
+ SSZ 1000 mg/day
FL Variant6 Variant 5 Variant 5 Variant 6
RA 6 53 F 2.27 MTX 10 mg/week
+ PSL 2 mg/day
Variant 5 Variant 5 Variant 5 Variant 5 Variant 5
DAS28, The Disease Activity Score in 28 joints; FL, full-length; IFX, infliximab; MTX, methotrexate; PSL, prednisolone; RA, rheumatoid arthritis; SSZ, sulphasalazine;
TAC, tacrolimus.
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As far as we know, this is the first report that hRasGRP4
is abundantly expressed in peripheral blood monocytes
from healthy individuals both at mRNA and protein
levels. This finding opens a new insight into the field of
monocyte-lineage cell biology and of the diseases where
this lineage cell plays a prominent role. In the latter part
of the present study, we revealed dysregulation of
hRasGRP4 in the PBMCs from patients with RA.
It has been concluded that the signaling protein
RasGRP4 plays a prominent role in the final stages of
development of mouse, rat, and human MCs [1,5,8].
Nevertheless, hRasGRP4 mRNA also has been detected
in an undefined population of cells in mouse and
human PBMCs [1]. In support of the latter data, the
hRasGRP4 transcript also has been found in the trans-
formed leukocytes isolated from a patient with acute
myeloid leukemia [4]. Although MC-committed pro-
genitors are present in the peripheral blood, these cells
a r er a r ei nn u m b e ra n dh a v eaC D 1 3
+/CD14
-/CD34
+/CD117
+ phenotype [28,32]. We, therefore, speculated
that another cell population might be responsible for
the presence of large amounts of RasGRP4 mRNA and
protein in normal mouse and human PBMCs. We now
show that the CD14
+ myeloid cells in PBMCs express
this GEF at the mRNA and protein levels (Figures 1A,
C). Only 26 dbESTs of the approximately 8.3 million
human dbESTs in the GenBank-UniGene database origi-
nated from the hRasGRP4 gene. Twelve of them are
from blood or bone marrow, followed by five from the
vector (-)
Figure 5 Forced expressions of hRasGRP4 and its splice variants in transcription-translation assay and in mammalian cells.A.C e l l - f r e e
transcription translation assay. The vectors encoding full-length hRasGRP4, its splice variant 5 and 6 were subjected to cell-free transcription
translation assay using rabbit reticulocyte lysate. Resulting products were subjected to immunoblotting using anti-hRasGRP4- horseradish
peroxidase (HRP). B. Expression of hRasGRP4 and its splice variants in mammalian cells. The vectors encoding full-length hRasGRP4, its splice
variant 5 or 6 were transfected into HEK293 cells. Cell lysates were subjected to immunoblotting using anti-hRasGRP4- HRP, anti-phospho or anti-
pan P44/42 mitogen-activated protein kinase (MAPK) (Erk1/2). Representative results of three independent experiments are shown.
Hashimoto et al. Arthritis Research & Therapy 2011, 13:R154
http://arthritis-research.com/content/13/5/R154
Page 10 of 13kidney. Thus, this signaling protein normally is highly
restricted in humans. More than 300,000 dbESTs have
been deposited in the database that originated from the
adult human lung. Although the lung contains large
numbers of macrophages, only one of the lung-derived
dbESTs in the database originated from the hRasGRP4
gene. In support of these dbEST data, the levels of the
RasGRP4 transcript in the mouse and human lung are
below detection by RNA blot analysis [1]. Because
hRasGRP4 mRNA and protein are below detection in
macrophage-rich organs and because human PBMCs
cease expressing hRasGRP4 when they are exposed to
lectins ex vivo [1], we conclude that the monocytes in
PBMCs cease expressing this signaling protein when
they differentiate into mature macrophages in tissues. In
agreement with this conclusion, in vitro-developed
human macrophages and osteoclasts contained much
lower hRasGRP4 mRNA levels when evaluated by qPCR
(Additional file 1/Figure S1).
Because monocytic cell lineages are indispensable
initiators/effectors in inflammatory arthritis, we next
focused on hRasGRP4 expression in patients with RA,
then evaluated hRasGRP4 expression in PBMCs from
RA patients both quantitatively and qualitatively. In the
present study, we note higher levels of hRasGRP4
mRNA (Figure 2) but also a higher frequency of certain
defective hRasGRP4 isoforms in the PBMCs from RA
patients (Figure 3 and Table 1). In our RA patients, the
expression levels of hRasGRP4 were not related to any
of investigated clinical and laboratory features. Alterna-
tively spliced isoforms of hRasGRP4 have been reported
in a patient with bronchial asthma, and were designated
splice variants 1, 2, and 4 [1]. Although we also detected
splice variants 1 and 2 transcripts in our cohort, the fre-
quencies of these variants were low. Instead, we identi-
fied 10 novel splice variants including 2 major variants
that are preferentially expressed in RA patients (Figure
3). The most abundant alternatively-spliced isoform was
splice variant 5. This variant lacks exon 9 but the
nucleotide sequence is kept in frame. The second abun-
dant splice variant 6 lacks 5’-portion of exon 9 and also
is in frame. This splice variant was scarcely found in
healthy individuals, despite its relatively high prevalence
in the patient group. In addition, splice variant 6 was
related to high levels of hRasGRP4 mRNA as quanti-
tated by qPCR. Because the probe used for qPCR theo-
retically recognizes the majority of the abnormal
hRasGRP4 isoforms, such as splice variants 5, 6, 9, and
1 1t o1 4 ,i ti sl i k e l yt h a tc e l l sw h i c hp r o d u c el a r g e
amounts of defective splice variants attempt to compen-
sate for that problem by producing more hRasGRP4
mRNA. In support of that conclusion, a naturally occur-
ring mRasGRP4 splice variant was identified in the MCs
developed from the C3H/HeJ mouse strain, which are
unresponsive to phorbol esters [2]. In bone marrow-
derived MCs developed from this mouse strain, the
levels of the transcripts that encode this defective
mRasGRP4 isoform were markedly higher relative to the
corresponding MCs developed from A/J mice that pre-
ferentially express the normal isoform of mRasGRP4.
The accumulated data suggest that when a certain line-
age of cells is unable to produce a normal/functional
signaling protein, such cells increase their production of
defective transcripts in an attempt to compensate for
the defective isoform. In fact, the peripheral blood cells
from RA patients fail to express a substantial amount of
normal hRasGRP4 protein (Figure 4A). Although splice
variant 5 lacks the entire exon 9 and splice variant 6
uses an alternative splice donor site in exon 9, we did
not find any point mutation in exon 9, splice donor site
and splice acceptor site of this exon, even when the
genomic DNA from a RA patient had exon 9 abnormal-
ity in all sequenced clones (data not shown). Although
the reason why hRasGRP4 transcripts are defective in
RA patients remains unclear, the presence of defective
hRasGRP4 transcripts does not appear to be a treat-
ment-induced phenomenon because non-treated RA
patients also had a high frequency of defective
hRasGRP4 cDNAs (Table 1). Other minor variants, such
as splice variants 7, 8, and 11 which lack exons 1 to 3
and splice variant 13 which lacks the 5’-portion of exon
12, do not have any premature translation termination
codon. Four of the other hRasGRP4 splice variants iden-
tified in our study comprise a premature translation-ter-
mination codon. Although these transcripts are
candidates for nonsense-mediated mRNA decay, if
translated, these splice variants would encode truncated
non-functional hRasGRP4 isoforms that have lost their
DAG/phorbol ester-binding sequence. How splicing of
hRasGRP4 is controlled in monocytes remains to be
determined in future studies. Functional aspects of alter-
native splicing of CD44 caused by its polymorphism
have been implicated in rheumatoid arthritis [33-35].
Although we could not clarify genetic predispositions
that are related to alternative splicing of RasGRP4, we
suggest that full-length RasGRP4 protein levels are regu-
lated, at least in part, by epigenetic factors such as alter-
native splicing.
Because exon 9 of hRasGRP4 encodes a large portion
of the conserved catalytic CDC25 box in hRasGRP4,
splice variants 5 and 6 are likely to be functionally
defective if translated in CD14
+ cells in vivo.I nf a c t ,a t
least in our mammalian cell expression system, splice
variant 6 was functionally defective in activating P44/42
MAPK when compared with normal hRasGRP4 (Figure
5B). Although the expression of splice variant 6 at the
protein level in monocytes from RA patients was
unclear, lower expression of RasGRP4 and/or that of
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development of monocytes into macrophages or osteo-
clasts, resulting in altered function of these cells in RA
patients.
Conclusions
W ec l a r i f i e dt h a th R a s G R P 4i se x p r e s s e di nt h eC D 1 4
+
monocytes in PBMCs. Because hRasGRP4 expression in
monocytes is likely to be developmentally controlled,
dysregulation of hRasGRP4 expression in peripheral
blood monocytes may affect the cell functions of further
differentiated cells such as macrophage and osteoclasts,
playing pathologic roles in a subset of RA patients.
Additional material
Additional file 1: Figure S1. Evaluation of hRasGRP4 transcripts in
CD14+ peripheral blood monocytes and in vitro cultured
macrophages or osteoslasts. A. hRasGRP4 transcripts in CD14+
peripheral blood monocytes and in-vitro cultured macrophages were
evaluated using real-time qPCR. The level of hRasGRP4 transcripts against
GAPDH in CD14+ cells at the first experiment was defined as 1. B.
hRasGRP4 transcripts in in-vitro cultured osteoclasts were measured by
real-time qPCR (left panel). Expression of cathepsin K (CTSK) was
measured to confirm the development of osteoclasts (right panel). In
these panels, amount of target gene transcripts against GAPDH
transcripts in PBMC at one experiment were defined as 1. All
experiments were done in a triplicate manner and error bars indicate
standard errors. OC, osteoclasts; PBMC, peripheral blood mononuclear
cells; RQ, relative quantification.
Additional file 2: Figure S2. hRasGRP4 transcript levels and the
ratios of monocytes in the peripheral blood. A. Relationship between
hRasGRP4 transcript levels in PBMC from RA patients and the ratio of
monocytes against the sum of monocytes plus lymphocytes. Linear
relationship between Relative Quantification of hRasGRP4 in PBMC and
the ratio of monocytes/(monocytes + lymphocytes) was measured using
Spearman’s rho analysis. B. Relationship between hRasGRP4 transcript
levels in PBMC from RA patients and percentage of monocytes in the
peripheral WBC. Linear relationship between Relative Quantification of
hRasGRP4 in PBMC and the percentage of monocytes in WBC was
measured using Spearman’s rho analysis. PBMC, peripheral blood
mononuclear cells; RQ, relative quantification.
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